Board summary
Key figures
31,095
Registered population
56.1% aged 18–64
31.6%
Aged 65+
ICB 20.0% · England 17.9%
0.6%
Ethnic minority (non-White)
0.3% Asian
0.0%
In IMD quintile 1
ICB 30.6% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,244
Hypertension register
+4.80% in 3 yrs · England +5.60%
245
SMI register
11.1% of Westmorland and Furness (LAD)'s
468
COPD register
Reviews +5.80% in 3 yrs
Forecast to 2030
6,947
Hypertension patients, 2030
+703 on today
53.3%
QRISK ≥20% on statins, 2030
+0.63pp over 3 yrs
7.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
QRISK lipid therapy trails England and ICB.
Only 52.0% of QRISK >= 20% patients receive lipid-lowering therapy (England 63.6%, ICB 61.4%), and 63.4% with CKD (England 70.3%), which could reflect recall.
SMI physical checks and heart failure reviews fell.
Over 2023 to 2025, SMI BP checks fell 2.5 pp (England +4.4 pp), BMI checks fell 1.0 pp, and heart failure reviews changed -3.2%.
Hypertension and diabetes control exceed national benchmarks.
Hypertension treatment to target reaches 72.9% (England 70.3%) with 93.9% having a recent BP reading, while frail diabetes HbA1c control reaches 86.3% (England 81.9%).
Population, age and ethnicity
Patients aged 65 and over represent 31.6% of the registered list against England's 17.9%
Patients aged 65+ make up 31.6% (9,840) of the 31,095 registered patients, above Westmorland and Furness (25.9%), NHS Lancashire and South Cumbria ICB (20.0%) and England (17.9%). Those aged 0–17 comprise 12.3% (3,819) and 18–64 represent 56.1% (17,436). Associated Census resident data records 99.4% White and a 0.6% ethnic minority share. Summed practice lists total 32,095 versus the PCN base of 31,095. This older age profile is consistent with higher demand for frailty care.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Westmorland and Furness (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Westmorland and Furness LA) | 1,591 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.2% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Westmorland and Furness LA) | 736 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Westmorland and Furness LA) | 10.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
PCN Core20 prevalence is 0.0% alongside an average IMD decile of 6.8
The PCN records 0.0% Core20 prevalence (0 estimated patients), below Westmorland and Furness (9.2%), NHS Lancashire and South Cumbria ICB (30.6%), and England (21.0%), with an average IMD decile of 6.8 (Westmorland and Furness 6.0, ICB 5.0, England 5.5). All seven member practices record 0.0% Core20. With no resident Core20 LSOAs captured, health inequality targeting may focus on clinical vulnerability across the PCN's 245 severe mental illness patients (11.1% of the borough register) and 107 learning disability patients (8.2%).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
245
SMI register
0.76% recorded prevalence
107
Learning disability register
0.33% recorded prevalence
10
Care homes, 239 beds
In the PCN catchment
The PCN records 107 learning disability patients (0.3% vs Westmorland and Furness 0.6%, NHS Lancashire and South Cumbria ICB 0.6%, England 0.6%) and 245 severe mental illness patients (0.8% vs Westmorland and Furness 0.9%, ICB 1.2%, England 1.0%), alongside 10 catchment care homes (239 beds). In Westmorland and Furness, rough sleeping was 14 in the 2025 autumn snapshot.
Severe mental illness: physical health checks
Across 245 severe mental illness patients, BP checks reached 82.3% (England 83.4%) but fell 2.5 pp over three years (England +4.4 pp). BMI checks reached 81.4% but fell 1.0 pp (England +5.1 pp), which could reflect unverified recall gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,244
Hypertension register
+4.80%
Register growth, 3 yrs
Westmorland and Furness (LAD) +6.93% · England +5.60%
+2.75pp
BP control, under 80
≤140/90 · +3.83pp aged 80+
+703
More patients by 2030
Forecast 6,947 (21.38%)
Hypertension case-finding and control
Recorded hypertension prevalence is 19.5% (6,244 patients), exceeding Westmorland and Furness (18.2%), the ICB (17.2%) and England (15.2%), consistent with an older population age structure. Practice prevalence ranges from 13.8% at Wraysdale House Surgery to 24.0% at Cartmel Surgery. Clinical control shows 93.9% have a recent blood pressure reading (England 90.0%) and 72.9% achieve treatment targets (England 70.3%), including 68.2% aged under 80 and 83.4% aged 80+. Three-year register growth of +4.8% trailed England (+5.6%). Strong blood pressure control places PCN management above England, but slower three-year register growth suggests opportunistic case-finding in lower-prevalence practices could be reviewed.
Lipids and statins
Lipid-lowering therapy lags England across high-risk groups: QRISK ≥ 20% coverage is 52.0% (England 63.6%), CKD is 63.4% (England 70.3%), and diabetes with CVD is 80.2% (England 84.4%). Fewer at-risk patients receive lipid-lowering therapy than national benchmarks, supporting a PCN review of high-risk prescribing recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 76,871 | £1.70 | £1.64 | £1.86 | £130,681 |
| Cardiovascular (all), 2025 | 111,708 | £2.84 | £3.38 | £3.33 | £317,251 |
For lipid-modifying drugs in 2026, the PCN prescribed 76,871 items at £1.70 per item (England £1.86, ICB £1.64). The PCN spent £12,299 less than at England's unit cost, but £4,612 more than at ICB unit cost. Spend per item sits below England but above ICB levels, alongside lower therapy coverage in high-risk cohorts.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+1.79%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.19%
Asthma prevalence, PCN 3-yr % change
The asthma register stands at 2,387 patients (7.7% vs England 6.6%). Annual reviews reached 68.3%, trailing Westmorland and Furness LAD (70.4%) while exceeding England (65.7%), leaving about 760 patients without a recorded review; reviews grew +1.8% over three years (England +4.4%). Paediatric asthma prescribing reached 1,925 items per 1,000 aged 5–19 (England 1,488). COPD prevalence is 1.5% (468 patients), with annual reviews at 79.9% (England 76.4%). Higher prescribing alongside unreviewed patients supports prioritising annual asthma reviews.
Cancer register and children's immunisation
Cancer register prevalence is 6.0% across 1,937 patients, exceeding England (3.8%) and Westmorland and Furness LAD (5.3%). In childhood immunisations, 6-in-1 coverage reaches 97.6% by 24 months (England 92.2%) but lags at 12 months at 89.4% (England 91.0%). At age 5, second-dose MMR (88.6%) and the 4-in-1 booster (84.1%) sit below the 95.0% target by 6.4 pp and 10.9 pp, which may reflect pre-school recall gaps.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
Across NHS Lancashire and South Cumbria ICB in 2022, 52.4% of staged cancers (4,642 of 8,863 with known stage) were diagnosed at stage 1 or 2, trailing England (55.3%) and 22.6 pp below the 75.0% national ambition by 2028 (about 2,010 extra cases needed), with the early-stage share falling 1.2 pp since 2013. Known stage was recorded for 74.6% of cases (8,863 of 11,883). Wider-system figures do not reflect PCN performance. Cancer prevalence is 6.0% (1,937 patients). Cervical screening coverage (aged 25–49) is 69.8% (England 66.8%, LAD 72.2%), dropping to 64.2% at Ambleside Health Centre and 56.8% at Windermere Health Centre.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For July 2026 (provisional), University Hospitals of Morecambe Bay NHS Foundation Trust met the 28-day faster diagnosis standard at 78.4% (standard 75.0%), in line with NHS Lancashire and South Cumbria Integrated Care Board (78.4%) and ahead of North Cumbria Integrated Care NHS Foundation Trust (78.3%) and Blackpool Teaching Hospitals NHS Foundation Trust (71.4%), against England's 79.3%. On the 62-day treatment standard, Morecambe Bay reached 72.4% (standard 85.0%), exceeding Blackpool Teaching Hospitals (67.5%), North Cumbria (70.9%) and England (71.2%), but below the ICB (73.6%). These waits describe provider performance rather than PCN referrals.
| Pathways within standard (%) | of Morecambe Bay | North Cumbria Integrated Care | Blackpool | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.39 | 78.33 | 71.38 | 78.39 | 79.32 |
| 31-day treatment (96%) | 95.22 | 93.09 | 97.96 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 72.35 | 70.90 | 67.48 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | of Morecambe Bay | North Cumbria Integrated Care | Blackpool | England |
|---|---|---|---|---|
| MRI | 4.04 | 9.59 | 21.80 | 21.40 |
| CT | 13.76 | 0.63 | 16.49 | 9.92 |
| Echocardiography | 10.55 | 1.33 | 7.57 | 28.48 |
| Colonoscopy | 0.60 | 5.50 | 13.08 | 30.83 |
| Gastroscopy | 1.45 | 10.90 | 12.47 | 29.02 |
| All 15 DM01 tests | 10.44 | 16.60 | 26.54 | 23.14 |
| Community services activity | Westmorland and Furness residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 53,485 | 193,720 |
| Referrals | 6,470 | 29,855 |
| Patients with a contact | 13,445 | 65,335 |
Community services (residents of Westmorland and Furness), Jun 2026 (provisional). In the Community Services Dataset for June 2026 (provisional), adults aged 65 and over accounted for 67.9% of all community contacts among borough residents (36,330 of 53,485 contacts). While reported for borough residents rather than registered PCN patients, this older-age share is consistent with the PCN demographic profile (31.6% aged 65+).
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Windermere | 120 | 0.0 | 86.6% | 78.7% | 96.6% |
| Cartmel Surgery | 103 | 0.0 | 98.6% | 75.9% | 96.0% |
| Wraysdale House | 90 | 0.0 | 93.8% | 67.8% | 95.2% |
| Haverthwaite | 125 | 0.0 | 95.2% | 74.2% | 95.2% |
| Nutwood Medical | 115 | 0.0 | 86.5% | 72.4% | 93.7% |
| Ambleside | 116 | 0.0 | 84.9% | 83.1% | 90.6% |
| St. Mary's Surgery | 106 | 0.0 | 89.1% | 82.5% | 90.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Heart failure reviews fell 3.2% over three years, while England rose +8.7%
Over three years, 13 measures trailed England. Heart failure functional reviews fell 3.2% (England +8.7%, LAD +1.7%, ICB +1.3%). Mental health checks fell 2.5 pp for blood pressure (England +4.4 pp) and fell 1.0 pp for BMI (England +5.1 pp), alongside unchanged alcohol recording at 0.0 pp (England +5.4 pp). In contrast, diabetes HbA1c control without frailty rose +7.7% (England +4.4%) to 61.2% (England 57.4%), and COPD reviews rose +5.8% (England +2.8%) to 79.9% (England 76.4%). These divergent trajectories could reflect differing recall workflows, although local causes are unconfirmed.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Dementia register
BP check (SMI)
BMI record (SMI)
Alcohol record (psychosis)
Diabetes HbA1c control
COPD reviews
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Westmorland and Furness (LAD) | Asset | PCN | Westmorland and Furness (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 10 (239 beds) | n/a | Schools (catchment) | 40 | n/a |
| Children's centres | 1 | 12 | Places of worship | 56 | 316 |
| Libraries | 4 | 14 | Food banks (VCS) | n/a | 2 |
| Day centres (VCS) | n/a | 2 | Children and young people (VCS) | n/a | 3 |
| Carers support groups (VCS) | n/a | 2 | Primary schools (LA maintained) | 15 | 82 |
| Primary academies | 3 | 27 | Special schools | 1 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured annual asthma review recall
Annual asthma reviews reached 68.3% across 2,387 patients, below Westmorland and Furness LAD (70.4%) and leaving about 760 patients unreviewed; three-year growth was +1.8% (England +4.4%). For discussion: run a structured annual review and inhaler check recall across the asthma register, offering flexible appointment slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
SMI physical health check outreach
Across 245 SMI patients, blood pressure checks (82.3% vs England 83.4%) fell 2.5 pp over three years (England +4.4 pp) and BMI checks (81.4% vs England 82.1%) fell 1.0 pp (England +5.1 pp). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Pharmacist-led lipid therapy recall
Lipid-lowering therapy for QRISK ≥ 20% is 52.0%, below LAD (59.6%), ICB (61.4%) and England (63.6%) by 11.5 pp, with three-year growth of +1.2% (England +6.2%). Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Frailty and list reconciliation review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Clinical vulnerability outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check audit (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension case finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · SMI physical health check outreach (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Option 3 · Pharmacist-led lipid therapy recall (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
